Dynavax Technologies (DVAX) Projected to Post Earnings on Thursday

Dynavax Technologies (NASDAQ:DVAX) will likely be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Dynavax Technologies to post earnings of $0.05 per share and revenue of $72.70 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $13.09 on Thursday. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $13.89. The firm’s fifty day simple moving average is $12.80 and its 200 day simple moving average is $11.98. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.72 billion, a PE ratio of 100.70 and a beta of 1.32.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DVAX shares. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. HC Wainwright raised their target price on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.